Nicotine transdermal

Nicotine Delivery Systems. For all transdermal nicotine products, the hypothesis is that continuous deflvery of nicotine [34-11-3] ne t trough levels during smoking should alleviate physical nicotine withdrawal symptoms and allow the smoker to concentrate on eliminating the behavioral aspects of addiction. [Pg.230]

Transdermal nicotine (i.e., the nicotine patch) is also available over the counter for smoking cessation. This form of nicotine dehvery may be espe-... [Pg.318]

Transdermal nicotine is available in a variety of formulations and dosing schedules (e.g., 15 mg/l6 hours 7, 14, and 21 mg/24 hours and 11 and 22 mg/ 24 hours) (Cinciprinni and McClure 1998). Peak nicotine concentrations for the various systems are reached 2-6 hours after application, and steady state conditions occur 2—3 days after continued patch use (Henningfield 1995). The highest-dose patch (i.e., 21 or 22 mg/24 hours or 15 mg/l6 hours) delivers approximately 0.9 mg of nicotine per hour transdermally (Henningfield... [Pg.319]

Joseph AM, Norman SM, Ferry LH, et al The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 335 1792-1798, 1996... [Pg.336]

Because smoking is associated with reduced symptoms of UC, nicotine has been studied as a potential treatment option. Transdermal nicotine may result in some improvement in mild to moderate UC symptoms. Daily doses between 15 and 25 mg appear to be most effective, but the role of nicotine therapy is not well defined.1... [Pg.288]

Nicotine patch Transdermal Nicotine gum Buccal Nicotine lozenge Buccal Nicotine nasal spray Intranasal 7-22 mg/day (started at 21 mg per day x 2 weeks then 14 mg per day x 2 weeks then 7 mg/day) 20-40 mg/day 2 or 4 mg/piece one piece every 2 hours up to 10 times/day 20-40 mg/day 2-4 mg/lozenge one lozenge every 2 hours, up to 10 times/day 16-32 mg/day 1-2 mg/spray, one in each nostril up to 16 times/day... [Pg.541]

Dose-dependent effects of transdermal nicotine on early morning awakening and rapid eye movement sleep time in nonsmoking normal volunteers. J. Clin. Psychopharmacol. 14, 264-7. [Pg.137]

Vazquez, J., Guzman-Marin, R., Salin-Pascual, R. J. 8r Drucker-Colin, R. (1996). Transdermal nicotine on sleep and PGO spikes. Brain Res. 737, 317-20. [Pg.143]

Gourlay S. G., Forbes A., Marriner T., Me Nei J. J. (1999). Predictor of adverse experiences during transdermal nicotine therapy. Drug Saf. 20, 545-55. [Pg.454]

Salin-Pascual R. J., de la Fuente J. R., Galicia-Polo L, Drucker-Colin R. (1995). Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology 121, 476-9. [Pg.458]

Stapleton JA, Russell MAH, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U and Wiseman D (1995). Dose effects and predictors of outcome in a randomised trial of transdermal nicotine patches in general practice. Addiction, 90, 31 42. [Pg.284]

Transdermal nicotine improved symptoms of patients with mild to moderate active ulcerative colitis in daily doses of 15 to 25 mg. [Pg.300]

Jorenby DE, Hatsukami DK, Smith SS, Fiore MC, Allen S, Jensen J, Baker TB. (1996). Characterization of tobacco withdrawal symptoms transdermal nicotine reduces hunger and weight gain. Psychopharmacology (Berlin). 128(2) 130-38. [Pg.454]

Pickworth WB, Fant RV, Butschky MF, Henningfield JE. (1996). Effects of transdermal nicotine deiivery on measures of acute nicotine withdrawai. J Pharmacol Exp Ther. 279(2) 450-56. [Pg.460]

Fant RV, Henningfleld JE, Shiffman S, Strahs KR, Reitberg DP (2000) A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol Biochem Behav 67(3) 479 82... [Pg.56]

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N (2006) Nicotine metabolite ratio predicts efiScacy of transdermal nicotine for smoking cessation, Clin Pharmacol Ther79(6) 600-608... [Pg.57]

Lawrence and colleagues (2002) explored the neural substrates of nicotine effects on sustained attention using the rapid visual information processing (RVIP) task. Smokers (n = 15) received either placebo or 21-mg transdermal nicotine patch prior to testing. Matched nonsmokers (n = 14) were tested under similar conditions, but did not receive a nicotine patch. Relative to the placebo condition, the smokers in the nicotine condition demonstrated improved task performance and increased neural activity in the parietal and occipital cortices, the thalamus and caudate, and decreased activity in left frontal, anterior and posterior cingulate, insula, and left parahippocampal regions (see Fig. 3). As noted by the authors, previous studies... [Pg.132]

Stein E, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, Hawkins M, Rao S, Bandettini PA, Bloom AS (1998) Nicotine-induced limbic cortical activation in the human brain a functional MRI smdy. Am J Psychiatry 155 1009-1015 Sziraki I, Lipovac MN, Hashim A, Sershen H, Allen D, Cooper T, Czobor P, Lajtha A (2001) Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats, Neurochem Res 26 609-617 Terborg C, Birkner T, Schack B, Witte OW (2002) Acute effects of cigarette smoking on cerebral oxygenation and hemodynamics a combined study with near-infrared spectroscopy and transcranial Doppler sonography, J Neurol Sci 205 71-75 Thompson JC, WUby G, Stough C (2002) The effects of transdermal nicotine on inspection time. Hum Psychopharmacol 17 157-161... [Pg.170]

Benowitz ML, Jacob P 3rd, Fong I, Gupta S (1994) Nicotine metabolic profile in man comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268 296-303 Benowitz NL, Perez-Stable EJ, Eong 1, Modin G, Herrera B, Jacob P 3rd (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291 1196-1203 Benowitz NL, Griffin C, Tyndale R (2001) Deficient C-oxidation of nicotine continued. Chn Pharmacol Ther 70 567... [Pg.252]

HU AL, Roe DJ, et al (2000) Efficacy of transdermal nicotine in reducing post-cessation weight gain in a Hispanic sample. Nicotine Tob Res 2(3) 247-253 Hogle JM, Curtin JJ (2006) Sex differences in negative affective response during nicotine withdrawal. Psychophysiology 43(4) 344-356... [Pg.287]

Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V (1996) Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression. J Clin Psychiatry 57 387-389... [Pg.365]

F%.1 Venous blood concentrations in nanograms of nicotine per miUimeter of blood as a function of time for various nicotine delivery systems. Data on the cigarette delivering about 1 mg nicotine (filled square), oral snuff delivering 3.6 mg (filled circle), and 4 mg nicotine gum (star) are from those published by Benowitz et al. (1988). Data on 1 mg nicotine nasal spray (filled triangle) are from Schneider et al. (1996). Data on 21 mg transdermal nicotine patch (open square) are from Benowitz (1993). Data on the 4 mg nicotine lozenge (open circle) are from Choi et al. (2003)... [Pg.491]

Currently approved NRT products include the transdermal nicotine patch and several acute NRT products, including nicotine gum, lozenge, sublingual tablet, vapor inhaler, and nasal spray. The single-dose nicotine plasma curves for transdermal patch, gum, nasal spray, lozenge, as well oral snuff and a cigarette, are illustrated in Fig. 1 (note for the sake of simphcity, the curve for sublingual tablet is not illustrated, but because of the route of nicotine delivery, the plasma curve is qualitatively similar to nicotine gum). [Pg.491]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...